Galectin-3 is considered as a biomarker of the severity of heart fibrosis.38 Acute and chronic renal failure can increase serum galectin-3 levels.39 Furthermore, heart transplantation does not seem to change serum levels of galectin-3 of patients with HF.40 Both biomarkers are now approved by the Food and Drug Administration as complementary biomarkers to assess the global risk of HF. The gene discussed is LGALS3; the disease is hydrops fetalis.